Synthesis and biological evaluation of the major metabolite of atomoxetine: elucidation of a partial kappa-opioid agonist effect

Bioorganic & Medicinal Chemistry Letters
Christopher J CreightonAllen B Reitz

Abstract

The major human metabolite of atomoxetine (4-hydroxyatomoxetine) was tested against a panel of receptors and enzymes, and was found to interact with the mu, delta, and kappa-opioid receptors based upon studies involving both binding and functional assays. 4-hydroxyatomoxetine was determined to be a partial agonist of the kappa-opioid receptor.

References

Aug 15, 1986·Science·A PfeifferH M Emrich
Apr 1, 1996·Journal of the American Academy of Child and Adolescent Psychiatry·T SpencerS Griffin
Mar 1, 1997·Journal of the American Academy of Child and Adolescent Psychiatry·C K Varley, J McClellan
Feb 21, 2002·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Barbara J RingSteven A Wrighton
Nov 15, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Frank P BymasterKenneth W Perry

❮ Previous
Next ❯

Related Concepts

Related Feeds

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.